Ascendiant Capital Markets Lowers 60 Degrees Pharmaceuticals (NASDAQ:SXTP) Price Target to $3.70

60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price objective decreased by research analysts at Ascendiant Capital Markets from $4.20 to $3.70 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target indicates a potential upside of 148.32% from the stock’s current price.

SXTP has been the topic of several other reports. HC Wainwright lowered 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen lowered 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 12th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, 60 Degrees Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $13.85.

60 Degrees Pharmaceuticals Price Performance

Shares of NASDAQ SXTP opened at $1.49 on Friday. The stock’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $2.86. 60 Degrees Pharmaceuticals has a one year low of $1.29 and a one year high of $14.68. The firm has a market cap of $3.96 million, a price-to-earnings ratio of -0.17 and a beta of 2.69.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.44 million. On average, equities analysts anticipate that 60 Degrees Pharmaceuticals will post -2.7 earnings per share for the current fiscal year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.